Results 51 to 60 of about 3,654 (190)

Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients

Perspectives in Clinical Research, 2021
Context: The Indian government is dispensing newer direct-acting antiviral (DAA) drugs, which may have impact on hepatitis C virus (HCV) patients’ quality of life (QoL).
Bhavya H Vyas, Nishita H Darji, Devang A Rana, Kaushal Y Vyas, Supriya D Malhotra   +4 more
doaj   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Efficacy and Safety of 12‐Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi‐Center Prospective Study

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT To assess the sustained virologic response (SVR12) and safety profile of 12‐week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)‐infected patients across genotypes in Northwest China. This prospective cohort study (2023–2024) enrolled HCV patients from 12 clinical centers in Northwest China, adhering to the China Hepatitis ...
Lu Yan, Maimaitijiang Wubuliaishan, Xiaoni Kou, Maimaitiaili Tuerxun, Mingbo Yang, Fanpu Ji, Yingli He, Jiuping Wang, Longdong Zhu, Xiaohong Gao, Fuchun Jing, Xiangchun Ding, Hong Du, Ye Zhang, Hong Jiang   +14 more
wiley   +1 more source

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

, 2015
BACKGROUND: A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.
Moreno, C, Feld, JJ, Asselah, T, Mangia, A, McHutchison, JG, Yoshida, E, Zeuzem, S, Ruane, PJ, Lai, CL, Jacobson, IM, Agarwal, K, Tran, TT, Mazzotta, F, Abergel, A, Gruener, N, Towner, WJ, Osinusi, A, Hézode, C, Shafran, SD, McNally, J, Zhu, Y, Chan, HLY, Svarovskaia, E, Brainard, DM   +23 more
core   +1 more source

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Post‐to Pretreatment Ratio of Serum CXCL10 Level Predicts Short‐Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct‐Acting Antiviral Therapy

Hepatology Research, Volume 56, Issue 5, Page 840-852, May 2026.
The post‐to pretreatment serum CXCL10 ratio was independently associated with short‐term liver function outcome following HCV eradication in cirrhotic patients. ABSTRACT Aim The prognostic value of serum C‐X‐C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)–infected patients with compensated or ...
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, Hayato Hikita, Masaru Enomoto, Atsunori Tsuchiya, Daiki Miki, Hiroshi Yatsuhashi, Hidekatsu Kuroda, Taro Yamashita, Hitoshi Yoshiji, Nobuharu Tamaki, Seiichi Mawatari, Hisamitsu Miyaaki, Yasuhiro Asahina, Yoichi Hiasa, Yoshihito Uchida, Yasunari Nakamoto, Taro Takami, Takahiro Kodama, Tetsuo Takehara   +20 more
wiley   +1 more source

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

, 2017
Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir ...
Eric Lawitz, Feld, JJ, Graham R. Foster, Bernard E. Willems, Norbert Bräu, Pearlman, B, Peter J. Ruane, Ira M. Jacobson, Robert H. Hyland, Tarik Asselah, Ronald G. Nahass, Dvory-Sobol, H, Jordan J. Feld, Shafran, SD, Thompson, AJ, Stamm, LM, Zhu, Y, Thomas Berg, Svarovskaia, E, Brainard, DM, Bräu, N, Berg, T, Asselah, T, Willems, BE, McHutchison, JG, Workowski, KA, Kosh Agarwal, Lawitz, E, Stephen D. Shafran, Brian Pearlman, Diana M. Brainard, G. Mani Subramanian, Stuart K. Roberts, Stedman, CAM, Dore, GJ, John G. McHutchison, Nahass, RG, Hadas Dvory-Sobol, Hyland, RH, Gane, EJ, Luisa M. Stamm, Catherine A.M. Stedman, Evguenia Svarovskaia, Jacobson, IM, Mitchell Davis, Agarwal, K, Bhandari, BR, Bal Raj Bhandari, Subramanian, GM, Borgia, SM, Roberts, SK, Alexander J. Thompson, Yanni Zhu, Ruane, PJ, Davis, M, Kimberly A. Workowski, Sergio M. Borgia, Gregory J. Dore, Dore, GJ ; https://orcid.org/, Foster, GR, Edward J. Gane   +60 more
core   +1 more source

Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir [PDF]

Background Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs).
Ruiz Cobo, Juan Carlos, Llaneras, Jordi, Rodríguez Seguel, Elisa del Pilar, Forns, Xavier, Arencibia, Ana, Gallego Moya, Adolfo, Conde Amiel, Isabel, Buti, María   +7 more
core   +3 more sources

Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications

Portal Hypertension &Cirrhosis, Volume 5, Issue 1, Page 65-95, March 2026.
Primary liver cancer remains a major global health burden, with China accounting for over 40% of cases. The predominant etiology is shifting from viral hepatitis to metabolic dysfunction‐associated steatotic liver disease (MASLD), while aflatoxin exposure and unhealthy lifestyles remain important contributors. Comprehensive control strategies—including
Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou   +12 more
wiley   +1 more source

Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review

Revista de Gastroenterología de México (English Edition), 2022
Introduction: The sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12
J.L. Pérez-Hernández, C.A. Arce-Salinas, R. Lehmann-Mendoza, A. Torre-Delgadillo, G.E. Castro-Narro, E. Cerda-Reyes, M.V. Ramos-Gómez, L. Juárez-Chavez, M. Dehesa-Violante, L.E. Muñoz-Espinoza, L.E. Cisneros-Garza, I. Aiza-Haddad, J.A. Velarde-Ruiz-Velasco, R. Contreras-Omaña, N. García-Casarreal, A. Carmona-Castañeda, F. Higuera-De la Tijera   +16 more
doaj   +1 more source